Events


Upcoming Events

2 March 2012, Tokyo, Japan
ICAAS General Assembly and Board Meeting 


Past Events

STOA hosted symposium: "The Changing Face of Risk Governance: Moving from Precaution to Smarter Regulation?"
29 September 2011 from 09:30 to 11:30, European Parliament, Strasbourg, France

Description:
Risk governance has changed remarkably over the last 100 years or so and continues to evolve form a purely reactive process based on demonstrated, significant levels of harms, to processes which attempt to counter future harm by making the risk governance more precautionary in nature.

However, the current EU regulation tendency is to move from precaution towards better or smarter regulation as part of the regulatory impact assessment programme.  The reform of comitology (new article 291) and the inter-institutional agreement have changed the dynamic and the regulatory interplay between the EU institutions;

This workshop includes contributions from STOA and the JURI and ENVI committees of the European Parliament, as well as from the European Commission and external experts on risk governance.

Event programme
Presentation: "Science Advice: Improving Regulatory Decisions through Targeted Research", Dr Rogers, ICAAS President
 


8th AAAW       

10 - 11 November 2011, Washington DC, USA

The eighth in a series of Amino Acid Assessment Workshops (AAAWs) was organized in the Ritz-Carlton Hotel in Georgetown (Washington DC, USA) on November 10 and 11, 2011. Sixty-five academic, government and industry experts from 11 countries attended the meeting. The Workshop was designed to continue a dialogue among experts in amino acid nutrition, metabolism, cell and molecular biology, toxicology and regulation/policy with the objective of establishing a framework for assessing and predicting the consequences of differing levels of leucine and tryptophan intake(s) in humans under various conditions. This year’s Day 1 morning session was organized and co-sponsored with the International Life Sciences Institute Research Foundation (ILSI RF) and focused on the ILSI RF approach to establishing upper limits for nutrients. Four speakers outlined the recent approaches to estimating upper limits for impurities and nutrients.

The remaining sessions during Day 1 and Day 2 focused on the safety of leucine and tryptophan. The presentations and discussions highlighted the outcome of ICAAS-sponsored research projects on both amino acids and underlined how the available data may be used to determine the upper level of the safe range of intake. In respect to leucine, the main speakers (Drs. Paul Pencharz from the Hospital for Sick Children, Toronto, Canada and Dr. Hisanori Kato from University of Tokyo, Tokyo, Japan) attempted to draw lessons from their research in rodents and humans. The acute study by Dr. Pencharz’s group was the first to directly estimate the safe upper limit of leucine intake in humans and raised concerns that intakes greater than 550 mg•kg-1•d-1 or ~39g/d may constitute a risk to health.

The tryptophan session was mainly focused on a literature review (by Dr. Ball from Univ. Alberta, Canada and Dr. Fernstrom from Uni. Pittsburgh, USA). The speakers explained that the upper limit of tryptophan catabolism may be a possible marker for the intake above which increasing intake increases the risk of adverse effects. There do not appear to be any published data on the upper limits to tryptophan oxidation. With various health benefits in mind, people had been using tryptophan supplements at doses up to 15 grams/day (200 mg/kg/day for a 70 kg individual), with typical doses of 5-8 g/day (70-100 mg/kg/day). The duration of the efficacy studies has been from 10-28 days (occasionally longer). Of interest in the present context, side effects, where reported, have generally been mild, or absent. The final speaker, Dr. Shibata (Shiga Pref. University, Japan), however, showed in rodent experiments that a tentative NOAEL ≥ 2,000 mg/kg body weight and LOAEL ≤ 5,000 mg/kg body weight may exist and that "the urinary excretory ratio of anthranilic acid/kynurenic acid" is potentially the most appropriate surrogate breakpoint index to predict the UL for tryptophan. This study is currently being followed by a human experiment with healthy female subjects. The Proceedings of the 8th AAAW will be published during 2012 as a supplement to the ”Journal of Nutrition” and the ICAAS members hope that the proceedings will be of assistance to both academicians and regulators who will be concerned with ULs for amino acids. ICAAS is predicated on providing the scientific base which should underpin any regulatory action in this field. The results reported during this workshop make this ambition concrete and will transform future debates on ULs for amino acids.
 


9-13 May 2011, Quebec, Canada
The 39th meeting of the Codex Committee on Food Labeling (CCFL) was organized in Quebec City (Canada) on May 9-13. Delegates from almost 100 member countries and dozens of observer NGOs participated in the meeting. The Committee was dealing with several key issues related to food labeling world-wide, including the labeling of foods derived from modern biotechnology. 

In this specific area, the Committee advanced a compromise statement on labeling of foods derived from modern biotechnology to Codex the Alimentarius Commission (CAC) for an adoption at step 5.8. In addition, major discussion was focused on sodium/salt labeling and nutrient and comparative claims. A WG created last year proposed an extensive list of conditions, which declared that “no-added salt” will be allowed only in foods which contain no added sodium salts, no ingredients that contain sodium salts (i.e., soy sauce, pickles) and two other conditions. For comparative claims, a threshold of a 25% decrease of content of the ingredient that is on the claim was preserved. 

 

 

 


 

3 March 2011 Dusseldorf, Germany
ICAAS General Assembly and Board meeting  

         


17 December 2010, Tokyo, Japan
On December 17, the Japanese chapter of ICAAS organized in Tokyo a 3-hour-long scientific seminar devoted to selected amino acids. Fifty participants were welcomed by the secretary of ICAAS Japan (Mr. Kobayashi), and thereafter attentively listened to a lecture on tryptophan metabolism and higher brain function, given by Professor Hiroshi Funakoshi from the Osaka University, Graduate School of Medicine.

Professor Funakoshi concentrated mainly on the role of the tryptophan metabolite, tryptophan 2,3-dioxygenase (TDO); the key enzyme in tryptophan metabolism in the brain. Recent studies indicate that TDO accelerates neurogenesis and emotional control.

Thereafter, Professor Toshio Hayashi from Nagoya University, School of Medicine described the recent research on effects of citrulline and arginine in arteriosclerosis using both rabbit and transgenic mouse models he developed a hypothesis that the positive effects of both citrulline and arginine in animal models of arteriosclerosis may be related to nitric oxide production. Both presentations were followed by lively discussion and a small social function.

                                

     Prof. Hayashi                            Final discussion                      Audience

      (Nagoya University,                    moderated by

      School of Medicine)                   Profs. Endo and
      during his presentation                 Kadowaki (left)